某院2018—2020年抗抑郁药物的应用分析

摘要/Abstract

摘要： 目的：评价并分析抗抑郁药的应用情况，为临床合理用药提供参考。方法：从某院药品管理系统中调取2018—2020年抗抑郁药物的使用量、销售金额等信息，计算用药频度（DDDs）、限定日费用（DDC）和销售金额排序与用药频度排序的比值（B/A）。结果：2018—2020年，某院抗抑郁药的总体销售金额呈升高趋势，临床上主要使用选择性5-羟色胺再摄取抑制剂（Selective serotonin reuptake inhibitors， SSRIs）与5-羟色胺和去甲肾上腺素再摄取抑制剂（Serotonin norepinephrine reuptake inhibitors， SNRIs）类抗抑郁药物。舍曲林、度洛西汀、文拉法辛和坦度螺酮的DDDs值基本稳居前5，而帕罗西汀、艾司西酞普兰、氯米帕明的DDDs 值下降。除帕罗西汀、艾司西酞普兰外其他各类药物的 DDC值基本保持稳定。2018—2020年内更多抗抑郁药物的B/A值等于或接近1。结论：该院抗抑郁药物的使用情况基本合理，新型抗抑郁药物或将成为临床首选。

关键词: font-size:medium, ">抗抑郁药；销售金额；用药频度；限定日消费；用药分析

Abstract: Objective：The clinical application of antidepressants were investigated and analyzed in the hospital to provide reference for clinical rational drug use. Methods：The quantity and sales amount of antidepressants in 2018-2020 were retrieved from information management system of the hospital. Defined daily dose system (DDDs)， defined daily cost (DDC)， and Ratio of sequence of sales amount and sequence of DDDs (B/A) were calculated. Results：During 2018 to 2020 the overall sales amount of antidepressants in the hospital showed an upward trend. Serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) were selected in clinical practice. The DDDs rankings of sertraline， duloxetine， venlafaxine and tandospirone were basically top five， while the DDDs values of paroxetine， escitalopram and clomipramine decreased. Except for paroxetine and escitalopram， the DDC values of other drugs remained stable. More antidepressants had B/A values (1or near 1) in 2018-2020. Conclusion：The use of antidepressant drugs in this hospital is basically reasonable and new antidepressant drugs may become the first choice in clinical practice.

Key words: Antidepressant, Sales amount, DDDs, DDC, Medication analysis

中图分类号:

马云海, 华玺, 徐凯, 肖楠, 杨海燕. 某院2018—2020年抗抑郁药物的应用分析[J]. 中国药物评价, 2022, 39(4): 358-362.

MA Yun-hai, HUA Xi, XU Kai, XIAO Nan, YANG Hai-yan. Analysis on the Use of Antidepressants in a Hospital from 2018 to 2020[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(4): 358-362.

参考文献

[1]Malhi GS， Mann JJ. Depression[J]. The Lancet， 2018，392(10161):2299-2312.
     [2]Liu J， Xun Z. Evaluation of the Effect of Comprehensive Nursing in Psychotherapy of Patients with Depression[J]. Comput Math Methods Med， 2021，2021:2112523.
     [3]Gonda X， Pompili M， Serafini G， Carvalho AF， Rihmer Z， Dome P. The role of cognitive dysfunction in the symptoms and remission from depression[J]. Ann Gen Psychiatry， 2015，14:27.
     [4]Olayinka MO. Somatic symptoms in depression: Evaluation of their diagnostic weight in an African setting[J]. British Journal of Psychiatry， 2004，184(5):422-427.
     [5]World Health Organization WHO(2017). Depression and Other Common Mental Disorders, Global Health Estimates[EB/OL]. (2017-02) [2022-04-01]. http://www.httpapps.who.intirisbitstream106652546101WHO-MSD.
     [6]Hutka P， Krivosova M， Muchova Z， et al. Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment[J]. Int J Mol Sci， 2021，22(3):1333.
     [7]陈新谦，金有豫，汤光. 新编药物学[M]. 北京：人民卫生出版社， 2011:283-296.
     [8]张冰，杨辉. 2012—2016年乌鲁木齐市第四人民医院抗抑郁药物的使用情况分析[J]. 现代药物与临床， 2018，33(5):1256-1261.
     [9]牛雅娟. 《中国抑郁障碍防治指南》药物治疗解读[J]. 临床药物治疗杂志， 2018，16(5):6-8.
     [10]Chen B， Zhang M， Ji M， et al. The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta-analysis of the Literature[J]. Neurochem Res， 2021，46(10):2731-2745.
     [11]张红芳. 我院SSRIs类抗抑郁药的应用与临床评价[J]. 基层医学论坛， 2009，13(7):278.
     [12]熊玉卿，殷嫦嫦，张会杰，等. 舍曲林在中国健康志愿者体内的药代动力学研究[J]. 中国药理学通报， 2006,(5):616-619.
     [13]Michael Bauer H-JM， Edith Schneider. Duloxetine: a new selective and dual-acting antidepressant[J]. Expert Opinion on Pharmacotherapy， 2006，7(4):421-427.
     [14]朱永，刘颖. 度洛西汀与舍曲林治疗抑郁症的临床疗效及不良反应[J]. 中国现代医生， 2021，59(5):121-124.
     [15]Miyahara Y， Funahashi H， Haruta-Tsukamoto A， et al. Time course of effects of venlafaxine on migraine and generalized pruritus in a patient with depression[J]. Clin Case Rep， 2021，9(11):e05088.
     [16]Bisserbe J. Clinical utility of milnacipran in comparison with other antidepressants[J]. International Clinical Psychopharmacology， 2002，17(suppl 1):S43-S50.
     [17]关燕玲，李福球，吴华顺. 对比米那普仑与度洛西汀治疗抑郁症的疗效和安全性[J]. 中国现代药物应用， 2022，16(3):217-219.
     [18]包志鹏，姜哲. 米氮平临床应用研究进展[J]. 黑龙江医药， 2010，23(4):600-602.